PRE-SEED ROUND OPEN

Invest In

Preventive Health.

We are a preventive healthcare company developing Class II medical devices to help prevent yeast infections and bacterial vaginosis—addressing an $18B market.

Let's Chat

TAM

$550B

Global Personal Care

SAM

$18B

Vaginal Health Market

$0M

$125B

Initial Target Share

MARGINS

78%

Target Gross Margin

The Urgent Need

Conditions like BV and yeast infections are not just nuisances—they are a public health crisis fueling antibiotic resistance.

46 Million

Women in the US affected annually.

40% Recurrence

Require antibiotics several times a year.

$4.8 Billion

Spent annually on ineffective reactive treatments.

The Antibiotic Cliff

As antibiotic resistance grows, traditional treatments are failing. The CDC identifies drug-resistant gonorrhea and associated bacterial imbalances as urgent threats. We are building the post-antibiotic defense system.

EW Labs: The Innovation

THE WORK

We engineer microbiome-safe, biofilm-disrupting formulas infused into daily essentials. We aren’t just making “clean” products; we are building medical-grade prevention.

THE NEED

The current standard of care is reactive: treat the infection after it happens. With recurrence rates skyrocketing and antibiotic efficacy declining, the market is desperate for a proactive solution.

THE BREAKTHROUGH

We are advancing the first preventive personal lubricant under FDA review as a Class II medical device—bridging the critical gap between consumer goods and clinical medicine.

Stong Early Traction

Validation from regulators, accelerators, and the market.

Community Growth

750+ email subscribers & 7,000+ social followers (100% organic).

Commercial Interest

6 retail LOIs secured. 3 women’s sports team LOIs and growing.

Non-Dilutive Funding

$250K grant awarded by State of Colorado (2:1 match by Feb 2026).

Regulatory Moat

First preventive personal lubricant under FDA review. AITC approved company.

Accelerators

Graduated from Generator gBeta and Innosphere accelerators.

Recent Comps

Honey Pot ($380M), Maven ($1B), Queen V (Undisclosed Exit).

“As a childhood cancer survivor and former Manager at Tesla & Rivian, I’ve focused my work on sustainable innovation and making our world a better place—now applied to an underserved area: the vaginal microbiome.”

REILLY WILLIAMS

Founder & CEO